Mon.Jan 27, 2025

article thumbnail

Pfizer settles Biohaven kickback claims case for $59.7m

Pharmaceutical Technology

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for preferential prescriptions.

Doctors 246
article thumbnail

Are we overlooking something critical in cell and gene therapy research?

Bio Pharma Dive

Taking control of O2 — ushering in the future of cell therapy research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tevogen Bio and Microsoft expand AI collaboration to PredicTcell tech

Pharmaceutical Technology

Tevogen Bio has expanded its partnership with Microsoft, aiming to further their collaboration centred on AI and advance PredicTcell.

173
173
article thumbnail

Akero says MASH drug reverses liver damage in study, doubling shares

Bio Pharma Dive

Results showing Akero’s efruxifermin improved fibrosis by more than what Wall Street expected lifted the stock of both it and rival MASH developer 89bio.

Drugs 167
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

The AI advantage in discovering new medicines 

Pharmaceutical Technology

With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

Medicine 162
article thumbnail

Sage rebuffs Biogen bid to take it over

Bio Pharma Dive

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to “maximize” shareholder value.

144
144

More Trending

article thumbnail

Muscle-building drug improves body composition in obesity trial, Veru says

Bio Pharma Dive

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Trials 144
article thumbnail

Eisai and Biogen’s LEQEMBI sBLA set for Alzheimer’s maintenance dosing

Pharmaceutical Technology

The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of Alzheimer's.

147
147
article thumbnail

Retail pharmacies: Biopharma’s bridge to better patient experiences and outcomes

Bio Pharma Dive

Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and personalized patient programs.

Pharmacy 130
article thumbnail

BIA report: UK biotech investment surged to £3.5bn in 2024

Pharmaceutical Technology

The UK biotech sector raised 3.5bn in 2024, the highest annual total since 2021 when 4.5bn was raised.

147
147
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

GSK backs £50m Oxford University cancer vaccine programme

pharmaphorum

A GSK alliance with Oxford University aims to identify precancerous changes in cells that could form the basis of preventive vaccines.

article thumbnail

Amgen opens new drug substance facility in North Carolina, US

Pharmaceutical Technology

Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North Carolina site.

Drugs 147
article thumbnail

Pfizer offers $60m to settle prescriber kickback claims

pharmaphorum

Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.

Drugs 102
article thumbnail

Trying Times for Biopharmaceuticals: How Researchers Can Flourish Amid Industry Challenges 

Pharmaceutical Technology

Where can researchers look for a beacon of hope amid trying times in the pharmaceutical industry? Read on for answers.

Research 130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Ascentage raises $126m in first biotech IPO of 2025

pharmaphorum

China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.

Drugs 98
article thumbnail

Vedanta Biosciences reveals Phase 2 VE303 results

Pharma Times

Study highlights VE303's potential in reducing recurrent CDI

83
article thumbnail

Six life sciences real estate trends to watch in 2025

pharmaphorum

Stay ahead of the game by keeping an eye on these six life sciences real estate trends to watch in 2025. From AI integration to collaborative incubator spaces, the industry is evolving rapidly.

article thumbnail

Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX

Pharma Times

Comparison shows improved survival rates for pancreatic cancer treatment

79
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

UK biotech Swarm lands with a T-cell therapy mission

pharmaphorum

UK firm Swarm Oncology launches with a T-cell therapy platform to treat solid tumours, with a Resolution Therapeutics co-founder in the pilot seat.

83
article thumbnail

FDA Accepts Review of Golimumab Biosimilar

Pharmaceutical Commerce

Known as AVT05, the Alvotech medication is a proposed biosimilar to Simponi, prescribed to treat various inflammatory conditions.

59
article thumbnail

Italian decision sets up launch of Oncopeptides' Pepaxti

pharmaphorum

Oncopeptides hopes to reignite growth in multiple myeloma drug Pepaxti after getting reimbursement approval in Italy.

Drugs 63
article thumbnail

Key Factors for Choosing a 3PL Provider

Pharmaceutical Commerce

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Amanda Salindong, associate director of channel & distribution at Alnylam Pharmaceuticals, shares the elements that manufacturers should consider when selecting a 3PL.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Understanding the Impact of Guillain-Barré syndrome

Pharma Tutor

Understanding the Impact of Guillain-Barr syndrome Pradip Mahajan Mon, 01/27/2025 - 15:41 Guillain-Barre syndrome (GBS) is an autoimmune disease. It's a rare neurological disorder that occurs when the body's immune system attacks its own peripheral nerves that carry signals from the brain and spinal cord to the rest of the body.

52
article thumbnail

Pharma Pulse 1/27/25: Digital Therapeutics with Abuse-Deterrent Pain Medication, Menopause Support and Workplace Change & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

52
article thumbnail

DDW Highlights: 27 January 2025

Drug Discovery World podcast

The latest episode of the DDW Highlightspodcast is now available to listen to below. DDWs Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week that Phesi revealed that breast cancer is the most studied disease for the fourth year in a row, we have seen a number of breakthroughs in the treatment of solid tumours, both in the early preclinical and later clinical stages of research.

Drugs 52
article thumbnail

Radiopharmaceutical Manufacturing: A Multi-Disciplinary Endeavour for Medical Imaging and Interventional Treatment

Roots Analysis

Nuclear medicine is a medical specialty that involves the use of radionuclides or radioactive tracers in conjunction with highly specialized imaging instrumentation to detect the emissions in the body after oral, inhalation, or intravenous administration of radionuclides. A radioactive tracer is a drug that is composed of a short-lived medical isotope tightly attached to a carrier molecule.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

FDA clears monthly dosing of Alzheimer’s drug Leqembi

Bio Pharma Dive

The approval is the first to come from the agency since the Trump administration paused all external communication from federal health agencies last week.

Drugs 144
article thumbnail

Building Tomorrow’s Therapies Today: The Evolution of Cell Therapy Manufacturing Process

Roots Analysis

The American Society of Gene and Cell Therapy (ASGCT) defines cell therapy as a therapeutic modality that involves the administration of either normal or modified cells to patients for the treatment of various diseases. In this form of therapy, patients are injected with living and intact human cells that are deemed to be capable of providing therapeutic benefit.

article thumbnail

FDA webpages on clinical trial diversity removed after Trump orders

Bio Pharma Dive

The website changes raise concerns about “the interference of politics with the study and the practice” of science and medicine, one physician said.

article thumbnail

January 27, 2025: Study Snapshot and Updated Ethics Documentation Available for TAICHIKNEE

Rethinking Clinical Trials

A new study snapshot and updated ethics and regulatory documentation are now available for the TAICHIKNEE trial. One year into the study, and after receiving approval to transition from the planning phase to the implementation phase, the research team reviewed and updated the minutes of their initial consultation with the Ethics and Regulatory Core.

Medicine 147
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.